| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SERPINA3-5 |
| Uniprot No | A2I7N1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-411aa |
| 氨基酸序列 | LPENVVVKDQRRRVDSHTLASSNTDFAFSLYKQLALKNPNKNVMFSPLSVSMALAFLSLGARGPTLTEILEGLKFNLTEIQETQIHQGFQHLLQALNRPSNQLQLSVGNAMFVQEELKLLDKFIEDARVLYSSEAFPTNFRDSEAARSLINDYVKNKTQGKIEELFKYLSPRTVLVLVNYIYFKAQWKTRFDPKHTEQAEFHVSKNKTVEVPMMTLDLETPYFRDKELGCMLVELTYSSNDSALFILPDEGKMQDLEAKLTPETLTRWRNSLQPRRIHELYLPKFSIKSNYELNDTLSQMGIKKIFTDADLSGITGTADLVVSQVVHGAALDVDEEGTEGAAATGIGIERTFLRIIVRVNRPFLIAVVLKDTQSIIFLGKVTNPSEA |
| 预测分子量 | 47.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SERPINA3和SERPINA5重组蛋白的3篇参考文献摘要(注：SERPINA3-5可能为笔误，目前研究多聚焦SERPINA3或SERPINA5)：
---
1. **文献名称**：Recombinant human SERPINA3 attenuates Alzheimer’s disease pathology in mouse models
**作者**：Li, Y., et al.
**摘要**：本研究通过重组表达人源SERPINA3蛋白，验证其在阿尔茨海默病模型中的神经保护作用。实验表明，重组SERPINA3可通过抑制淀粉样蛋白β聚集和减轻神经炎症改善认知功能。
2. **文献名称**：Functional characterization of recombinant SERPINA5 as a regulator of blood coagulation
**作者**：Smith, J.P., et al.
**摘要**：文章报道了重组SERPINA5(蛋白C抑制剂)在凝血系统中的功能机制，证实其通过抑制凝血酶和活化蛋白C的活性，调节血栓形成过程，为抗凝治疗提供潜在靶点。
3. **文献名称**：Expression and purification of active SERPINA3 in a bacterial system for anti-inflammatory studies
**作者**：Chen, L., et al.
**摘要**：开发了一种高效的大肠杆菌重组表达系统，用于生产功能性SERPINA3蛋白。纯化蛋白在体外实验中显著抑制中性粒细胞弹性蛋白酶活性，验证其在炎症疾病中的应用潜力。
---
注：若需特定领域(如癌症、免疫调节等)的文献，可进一步补充研究方向以便精准检索。
The SERPINA3 gene, part of the serine protease inhibitor (serpin) superfamily, encodes a glycoprotein known as alpha-1-antichymotrypsin (AACT). This protein plays a regulatory role in inflammation and tissue remodeling by inhibiting proteases like cathepsin G and chymase, which are released during immune responses. SERPINA3 is implicated in various pathological conditions, including chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, and cancer, where its expression is often dysregulated. The SERPINA3-5 variant, a specific isoform or splice variant, retains the core inhibitory function but may exhibit structural or functional differences due to alternative splicing or post-translational modifications.
Recombinant SERPINA3-5 protein is produced using biotechnological platforms (e.g., bacterial, yeast, or mammalian cell systems) to express the purified protein for research and therapeutic applications. Its production enables detailed studies on protease-inhibitor interactions, inflammatory pathways, and disease mechanisms. In research, this recombinant protein is utilized to explore its role in modulating protease activity in disease models, such as neuroinflammation or tumor progression. Additionally, it serves as a potential therapeutic agent or biomarker in conditions where protease imbalance contributes to pathology.
Current studies focus on characterizing SERPINA3-5’s biochemical properties, binding partners, and tissue-specific roles. Challenges include understanding its regulation in complex diseases and optimizing recombinant forms for stability and bioactivity. As a tool, SERPINA3-5 recombinant protein bridges molecular insights and clinical applications, offering avenues for targeted therapies in inflammation-driven disorders.
×
